OLANZAPINE TEVA ® 7.5 MG

Pays: Israël

Langue: anglais

Source: Ministry of Health

Ingrédients actifs:

OLANZAPINE 7.5 MG

Disponible depuis:

SALOMON,LEVIN & ELSTEIN LTD

Code ATC:

N05AH03

forme pharmaceutique:

FILM COATED TABLETS

Mode d'administration:

PER OS

Fabriqué par:

TEVA OPERATIONS POLAND SP.ZO.O

Groupe thérapeutique:

OLANZAPINE

indications thérapeutiques:

Acute and maintenance treatment of schizophrenia. Olanzapine Teva® is indicated for the management of the manifestations of psychotic disorders. Olanzapine Teva® is indicated for the short-term treatment of acute manic episodes associated with Bipolar I Disorder.Prevention of recurrence in Bipolar Disorder: In patients whose manic episode has responded to olanzapine treatment Olanzapine Teva® is indicated for the prevention of recurrence in patients with Bipolar Disorder. Combination therapy in Bipolar I Disorder. The combination of Olanzapine Teva® with lithium or valproate is indicated for the short-term treatment of acute manic episodes associated with Bipolar I Disorder.

Date de l'autorisation:

2011-04-01